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ABSTRACT The signaling molecule cyclic diguanylate (c-di-GMP) mediates physio-
logical adaptation to extracellular stimuli in a wide range of bacteria. The complex
metabolic pathways governing c-di-GMP synthesis and degradation are highly regu-
lated, but the specific cues that impact c-di-GMP signaling are largely unknown. In
the intestinal pathogen Clostridium difficile, c-di-GMP inhibits flagellar motility and
toxin production and promotes pilus-dependent biofilm formation, but no specific
biological functions have been ascribed to any of the individual c-di-GMP synthases
or phosphodiesterases (PDEs). Here, we report the functional and biochemical char-
acterization of a c-di-GMP PDE, PdcA, 1 of 37 confirmed or putative c-di-GMP metab-
olism proteins in C. difficile 630. Our studies reveal that pdcA transcription is con-
trolled by the nutrient-regulated transcriptional regulator CodY and accordingly
increases during stationary phase. In addition, PdcA PDE activity is allosterically regu-
lated by GTP, further linking c-di-GMP levels to nutrient availability. Mutation of
pdcA increased biofilm formation and reduced toxin biosynthesis without affecting
swimming motility or global intracellular c-di-GMP. Analysis of the transcriptional re-
sponse to pdcA mutation indicates that PdcA-dependent phenotypes manifest dur-
ing stationary phase, consistent with regulation by CodY. These results demonstrate
that inactivation of this single PDE gene is sufficient to impact multiple c-di-GMP-
dependent phenotypes, including the production of major virulence factors, and
suggest a link between c-di-GMP signaling and nutrient availability.
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The anaerobic, Gram-positive bacterium Clostridium difficile is the most commoncause of nosocomial infections in the developed world, resulting in symptoms
ranging from mild diarrhea to potentially lethal pseudomembranous colitis (1). C.
difficile exposure rarely results in symptomatic infections in healthy individuals, as a
healthy microbiota creates an environment that hinders C. difficile growth (2, 3). The
main risk factor for an initial C. difficile infection is disruption of the gut microbiota by
antibiotic treatment, which creates a transient “nutrient bloom” due to drug-induced
disruption of normal bacterial metabolism (4–7).
The C. difficile life cycle has two distinct phases with different roles in disease:
metabolically active vegetative cells and dormant spores. C. difficile spores are resistant
to oxygen, heat, and many commercial disinfectants, making their eradication from
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contaminated environments difficult (8–10). In the anaerobic mammalian intestine,
spores germinate into vegetative cells, a process triggered by chemical signals includ-
ing certain amino acids and bile acids (11, 12). Vegetative C. difficile cells secrete protein
cytotoxins that drive the development of disease symptoms (13, 14). These cytotoxins,
TcdA and TcdB, are internalized by host epithelial cells, where they glucosylate and
inactivate the Rho and Rac GTPases that regulate the host actin cytoskeleton (15–18).
Intoxication leads to actin depolymerization, with cytopathic effects including cell
rounding and disruption of cell-cell tight junctions, which effectively permeabilizes the
intestinal epithelium (13, 14, 19). C. difficile toxins are capable of inducing apoptosis and
necrosis in intoxicated cells (20, 21). The effects of these toxins result in diarrhea and
trigger a massive inflammatory response in the host (14, 22, 23).
During infection, C. difficile cells can either remain vegetative or differentiate into
spores, which are shed in stool and allow transmission of C. difficile to new hosts (24).
The factors that influence the balance between vegetative growth and sporulation in
vivo are poorly understood. There is growing evidence that nutrient uptake from the
environment inhibits the onset of sporulation, as spore formation is negatively regu-
lated by nutrient transporters (25, 26). In vegetative C. difficile, nutrient availability also
modulates the activity of CodY, a transcriptional regulator that is conserved among
low-GC Gram-positive bacteria. When CodY is activated by binding of branched-chain
amino acids (BCAA), it binds to target DNA sequences and primarily represses gene
transcription (27). In some organisms, including C. difficile, CodY is also activated by GTP
(28–30). When BCAA and GTP are abundant, such as in exponential phase, CodY
represses the transcription of stationary-phase metabolic genes such as amino acid
synthetases and peptide transporters (31, 32). Intracellular stores of BCAA and GTP
become limited during stationary phase (28, 33, 34), relieving CodY repression of these
genes. In a number of Gram-positive pathogens, including C. difficile, Staphylococcus
aureus, and Listeria monocytogenes, CodY represses the transcription of virulence factor
genes during exponential growth (30, 35–38). Microarray analysis and affinity purifica-
tion of CodY binding targets have revealed that CodY regulates the transcription of
hundreds of C. difficile genes, including some with predicted roles in signaling by the
second messenger cyclic diguanylate (c-di-GMP) (27).
In a multitude of Gram-negative bacteria, c-di-GMP regulates transitions between
motile, planktonic lifestyles and sessile modes of growth, often involving biofilm
formation (39). In several Gram-negative pathogens, c-di-GMP also influences virulence
(40–45). The regulatory roles of c-di-GMP in Gram-positive bacteria are less well
characterized but appear to be largely conserved with Gram-negative species, with
elevated c-di-GMP inhibiting swimming motility and promoting nonmotile lifestyles
(46).
c-di-GMP is synthesized from GTP by diguanylate cyclase (DGC) enzymes containing
a characteristic GGDEF domain (47) and degraded by two families of phosphodiesterase
(PDE) enzymes identified by conserved EAL or HD-GYP domains (48, 49). Bacterial
genomes commonly contain multiple genes encoding these domains, which are often
coupled to sensory or regulatory domains (50, 51). The C. difficile 630 genome encodes
37 DGCs and PDEs (52). The c-di-GMP-metabolizing activity of 28 of these enzymes has
been confirmed by heterologous expression in Vibrio cholerae and/or Bacillus subtilis
(53, 54). Elevated cytoplasmic levels of c-di-GMP repress C. difficile flagellar biosynthesis
and toxin production and enhance type IV pilus biogenesis and biofilm formation
(55–60). c-di-GMP also appears to regulate the production of clostridial proteins that
interact with the mammalian extracellular matrix, suggesting a role for c-di-GMP in the
regulation of adhesion to host cells (56, 61–63). While c-di-GMP regulates multiple
processes with a known or potential role in virulence, specific functions have not yet
been ascribed to any of the individual C. difficile DGCs or PDEs.
In this study, we examined the transcriptional and posttranslational regulation of
the C. difficile c-di-GMP PDE PdcA and determined its role in the regulation of c-di-
GMP-dependent processes. We show that pdcA is a stationary-phase gene regulated by
CodY and that PdcA enzymatic activity is regulated by GTP via its GGDEF domain,
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indicating that nutrient availability impacts c-di-GMP signaling in C. difficile. Notably,
mutation of pdcA impacts multiple c-di-GMP-regulated processes, including biofilm
formation and toxin production. Thus, this study identified a single c-di-GMP PDE
capable of broadly affecting C. difficile c-di-GMP signaling during stationary phase.
RESULTS
The PAS and GGDEF domains affect PdcA function in vitro and in vivo. We
previously reported that full-length PdcA and its EAL domain alone exhibit c-di-GMP
PDE activity in vitro but that overproduction of the PdcA EAL domain alone had no
detectable effect on the cytoplasmic c-di-GMP concentration or flagellar motility of C.
difficile (55). Heterologous overproduction of full-length PdcA in V. cholerae or B. subtilis
increases motility and decreases V. cholerae biofilm formation, consistent with de-
creased c-di-GMP (53, 54), leading us to hypothesize that the other domains of PdcA are
required for activity of the EAL domain in vivo. Full-length PdcA is a PAS-GGDEF-EAL
fusion protein (Fig. 1A). The PdcA EAL domain contains a valine substitution for the
alanine in the canonical EAL motif (i.e., EVL). While the glutamic acid in the EAL
sequence is required for PDE activity, the alanine residue has been shown previously to
be dispensable (42, 55). The PAS domain is part of a family of regulatory domains that
can bind diverse small-molecule ligands and often regulates protein activity through
protein-protein interactions (64). The PdcA GGDEF domain contains a degenerate
active site (DGDEM) and has been demonstrated to be catalytically inactive (55). In
FIG 1 PdcA enzymatic activity is controlled by regulatory domains in vitro and in vivo. (A) Schematic of the PdcA
derivatives used in these experiments with the corresponding symbols and colors used in panels B to D. The EAL
domain of PdcA contains a substitution of valine for alanine in the EAL motif, noted here as EVL. (B) Percentages
of initial c-di-GMP substrate hydrolyzed by full-length PdcA, PdcA(GA), PdcAΔPAS, and PdcA-EAL, determined at
1-min intervals after initiation of the reaction upon addition of the substrate. Open circles indicate values for
buffer-only negative controls. The data shown are mean values and standard deviations from three [WT and
PdcA(GA)] or two (PdcAΔPAS and PdcA-EAL) separate protein purifications. (C) PDE activity, expressed as a
percentage of the starting c-di-GMP hydrolyzed at 1 min with increasing concentrations of GTP. The data shown
are mean values and standard deviations. The activity of full-length PdcA (blue) and PdcAΔPAS (purple) at a given
GTP concentration was compared to the activity of the same protein in the absence of GTP by one-way analysis
of variance (*, P 0.05; **, P 0.01; ***, P 0.001; asterisks are color coded according to comparison). The activities
of PdcA(GA) and PdcA-EAL in the presence of GTP were compared to their activities in the absence of GTP by
one-way analysis of variance and were not statistically significantly different at any of the GTP concentration tested
(not shown). (D) C. difficile strains with (left to right) the vector (v), pPdcA, pPdcA(GA), pPdcAΔPAS, or pPdcA-EAL
were assayed for motility in BHIS-Tm with 0.3% agar supplemented with 0 or 5 g/ml nisin. Motility diameters were
measured after 72 h at 37°C. Data were analyzed by two-way analysis of variance and Bonferroni’s multiple-
comparison test comparing values to the average vector control value (**, P  0.01).
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some homologous proteins with tandem GGDEF-EAL domains, catalytically inactive
GGDEF domains are capable of binding GTP, which enhances the PDE activity of the
associated EAL domains (65–68). Crystal structures of catalytically active and inactive
DGCs suggest that the small side chain of the glycine at position 2 creates a binding
pocket for the guanine base of GTP, while the aspartic acid at position 4 coordinates a
magnesium ion that interacts with the phosphates (69–71). These residues are con-
served in PdcA, suggesting a regulatory role for its GGDEF domain.
To examine the potential regulatory effects of the PAS and GGDEF domains on PdcA
enzymatic activity, we analyzed the full-length protein and three derivatives: full-length
PdcA in which the putative DGDEM cyclase active-site residues are mutated to alanines
[PdcA(GA)], a truncated protein with no N-terminal PAS domain (PdcA-ΔPAS), and the
isolated PDE domain (PdcA-EAL) (Fig. 1A). The enzymatic activities of these recombi-
nant proteins, along with wild-type (WT) PdcA, were assayed in vitro with radioactive
c-di-GMP as a substrate. All of these proteins hydrolyzed c-di-GMP to various degrees
(Fig. 1B). To determine whether GTP binding to the GGDEF domain stimulates hydro-
lytic activity by the EAL domain, we assayed c-di-GMP cleavage in the presence of
increasing amounts of GTP. WT PdcA activity was increased 50% by the addition of one
molar equivalent of GTP and increased in a dose-dependent manner at higher GTP
concentrations (Fig. 1C). PdcA-ΔPAS, which has an intact DGDEM sequence, was less
responsive to low levels of GTP than the WT but also displayed a dose-dependent
GTP-stimulated increase in PDE activity (Fig. 1C). The enzymatic activities of PdcA(GA)
and PdcA-EAL, both of which lack the DGDEM putative GTP-binding motif, were
unaffected by GTP (Fig. 1C). The results are consistent with allosteric activation of PDE
activity of the EAL domain as a result of GTP binding to the DGDEM sequence in the
GGDEF domain, as has been observed for several other tandem GGDEF-EAL proteins
with degenerate GGDEF domains (65–68). The PdcA-ΔPAS protein was slightly less
active than the full-length protein in vitro (Fig. 1B), suggesting an as-yet-undefined
regulatory function for the N-terminal PAS domain.
We next evaluated the roles of the PdcA regulatory domains in vivo by comparing
the effects of overproducing WT PdcA or the PdcA(GA), PdcA-ΔPAS, or PdcA-EAL
derivative in C. difficile. The genes for these PdcA variants were expressed in C. difficile
with a plasmid-borne expression system in which sublethal concentrations of the
antimicrobial peptide nisin induce gene expression (55). We did not assay biofilm
formation in these strains, as the C. difficile 630 strain does not form very dense biofilms
(60, 72), so the anticipated decreases upon PDE overproduction would likely be subtle.
We have previously reported that overproduction of PdcA-EAL does not impact flagellar
motility within 96 h (55). Here, C. difficile overproducing WT full-length PdcA exhibited
a significant, nisin-dependent increase in motility compared to the vector control strain
by 72 h, consistent with reduced c-di-GMP upon WT PdcA overproduction (Fig. 1D).
Overproduction of PdcA(GA), PdcA-ΔPAS, or PdcA-EAL did not significantly affect
motility, indicating that the PAS and GGDEF regulatory domains are necessary for
maximal PdcA enzymatic activity in vivo.
pdcA transcription is regulated by CodY. Previous studies have demonstrated that
PdcA, 1 of 19 EAL domain proteins encoded in the C. difficile genome, is a functional
c-di-GMP PDE (53–55). However, the contribution of PdcA to c-di-GMP signaling in C.
difficile is unknown. Previous transcriptional profiling studies suggested that pdcA
expression is greater during stationary phase than during exponential growth and is
reduced in C. difficile lacking SigH, a sigma factor involved in the onset of stationary
phase and the initiation of spore formation (73). In addition, a study aimed at identi-
fying DNA sequences bound by the transcription factor CodY in C. difficile identified a
sequence overlapping the 5= end of the pdcA coding sequence (CD630_15150) (27, 30).
To determine whether pdcA transcription shows CodY-dependent growth phase reg-
ulation, we performed quantitative reverse transcription-PCR (qRT-PCR) to evaluate
transcript abundance in C. difficile mRNA harvested during exponential-phase and early
stationary-phase growth. Two stationary-phase genes previously shown to be regu-
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lated by CodY, ilvC and tcdR, served as positive controls (30). In WT cells (JIR8084, a
derivative of C. difficile 630), the pdcA transcript was three times as abundant in
stationary phase as in log phase (Fig. 2). Similar results were obtained for ilvC and tcdR,
which were 12- and 20-fold more abundant during stationary phase, respectively. In a
codY mutant, transcript levels of pdcA, ilvC, and tcdR were higher than in the parent
strain (2-, 12-, and 20-fold higher, respectively) during exponential phase, indicating
derepression of these genes in the absence of CodY (Fig. 2). Stationary phase onset in
the codY null strain caused no significant further increase in pdcA or ilvC transcripts, and
the tcdR transcript showed a modest 3-fold increase (Fig. 2). Thus, expression of all
three genes during exponential growth was repressed in WT C. difficile and not in the
codY null strain, indicating that pdcA is a bona fide CodY-regulated gene expressed
during stationary phase (27).
Though Dineen et al. identified a DNA region encompassing the pdcA translational
start site by affinity purification with CodY, the putative pdcA promoter region lacked
a recognizable CodY consensus binding sequence by the specified criteria (27, 30). We
used electrophoretic mobility shift assays (EMSAs) to determine whether CodY binds
pdcA promoter DNA. We chose a DNA region containing the 194-bp sequence pulled
down by CodY, which includes the first 146 bp of the pdcA coding sequence (27), plus
an additional 261 bp of the upstream sequence. GTP and BCAA leucine, isoleucine, and
valine, which stimulate CodY binding to target DNA in C. difficile, were included in the
binding reaction mixtures, and the amino acids were added to the electrophoresis
buffer (30). CodY had no effect on the migration of the 133-bp nonspecific, negative
control DNA fragment of V. cholerae gbpA included in each binding reaction mixture. As
shown previously, CodY bound to and shifted the migration of the ilvC promoter
region, which served as a positive control (Fig. 3A) (27). Similarly, CodY bound to the
pdcA promoter fragment (Fig. 3B). These results suggest that CodY negatively regulates
pdcA transcription by binding directly to the pdcA promoter.
Mutation of pdcA specifically affects stationary-phase phenomena. Despite
using multiple targeting sequences, we were unsuccessful in generating a pdcAmutant
via insertional inactivation by a targeted intron (74). As an alternative, we replaced the
pdcA open reading frame (ORF) with the catP gene by allelic exchange. We cloned the
2,000-bp sequences upstream and downstream of pdcA into pMC234 flanking the catP
gene (see Fig. S1 in the supplemental material). The construct was introduced into C.
difficile 630 by conjugation. After the identification of a thiamphenicol-resistant
recombinant strain in which the plasmid had recombined into the chromosome at
the pdcA locus, it was passaged without selection to allow plasmid loss. The
resulting thiamphenicol-sensitive isolates were screened by PCR to identify an isolate in
FIG 2 CodY regulates pdcA transcription. Transcript levels of the genes indicated in WT JIR8094
(erythromycin-sensitive derivative of C. difficile strain 630) and an isogenic codY-null strain in exponential
phase (black) and stationary phase (gray) were measured by qRT-PCR. The data were analyzed by the
ΔΔCT method as described in Materials and Methods, here with exponential-phase WT cells as the
reference condition. The mean values and standard deviations from three biological replicates are shown.
The data were analyzed by unpaired t test comparing the exponential- and stationary-phase transcript
levels of each gene (*, P  0.05; ***, P  0.001).
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which pdcA had been replaced on the chromosome with catP by double homologous
recombination (Fig. S1) (75).
The resulting pdcA::catP mutant was assessed for altered c-di-GMP and related
phenotypes, including flagellar motility, biofilm formation, and toxin production (55,
57). The cytoplasmic c-di-GMP concentrations of the WT and pdcA::catP deletion C.
difficile strains grown to early stationary phase were assayed by ultraperformance liquid
chromatography coupled to mass spectrometry (UPLC-MS) and found to be indistin-
guishable (Fig. 4A), indicating that the absence of PdcA does not impact global
FIG 3 CodY binds directly to the pdcA promoter region. Purified six-histidine-tagged C. difficile CodY was
tested for the ability to bind the pdcA promoter region with EMSAs. Serial 2-fold dilutions of CodY were
incubated with the ilvC promoter region previously shown to be directly bound by CodY (A) or the pdcA
promoter region (B). As a negative control, a 133-bp V. cholerae DNA fragment was included in each
binding reaction mixture (asterisks). The concentrations of CodY used were (left to right) 0, 7.2, 3.6, 1.8,
0.9, 0.45, 0.23, 0.12, and 0.06 M. In each reaction mixture and in the electrophoresis buffer, isoleucine,
leucine, and valine were added to promote CodY binding. A representative of three independent
experiments is shown. The values to the left are molecular sizes in kilodaltons.
FIG 4 pdcA affects biofilm formation but not swimming motility or global c-di-GMP levels of C. difficile. (A) c-di-GMP
in the cytoplasm of the 630 WT and pdcA::catPmutant C. difficile strains was quantified by UPLC-MS and normalized
to the total cellular protein level. The mean values and standard deviations of six biologically independent samples
are shown. (B) Swimming motility through BHIS–0.3% agar was measured at 24, 48, and 72 h. The mean values and
standard deviations of six biologically independent samples are shown. (C) Biofilm formation assayed by crystal
violet staining after 24 h of growth. The mean values and standard deviations of five biologically independent
samples are shown. **, P  0.01 by unpaired t test. (D, E) Complementation analysis of biofilm formation after 24
h of growth. pRT1099 is the vector control, pRT1214 encodes PdcA, and pRT1662 encodes a catalytically inactive
form of PdcA. (D) Representative image of crystal violet-stained biofilms. (E) Quantification of biofilm biomass by
crystal violet staining. The mean values and standard deviations of three biologically independent samples are
shown. **, P  0.05 by one-way analysis of variance and Dunnett’s multiple-comparison test.
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c-di-GMP levels under these growth conditions. C. difficile motility through brain heart
infusion medium with 0.5% yeast extract (BHIS) and 0.3% agar, which is inhibited by
high levels of c-di-GMP, was also not altered in the pdcA::catP mutant (Fig. 4B). In
contrast, biofilm formation, which is positively regulated by c-di-GMP (56, 60), was
modestly but significantly higher in the pdcA::catP mutant strain than in the WT (Fig.
4C). The pdcA::catPmutant expressing pdcA from a plasmid (pRT1214) under the control
of its native promoter produced biofilm comparably to the WT bearing the control
vector (pRT1099) (Fig. 4D and E). Expression of an allele of pdcA encoding an enzy-
matically inactive PdcA protein in the pdcA::catP mutant (pdcA E479A allele, pRT1662)
did not restore biofilm formation to WT levels (Fig. 4D and E), indicating that PdcA
controls biofilm production via c-di-GMP hydrolysis. Thus, although the pdcA mutation
does not affect global c-di-GMP levels during early stationary phase and does not alter
motility through 0.3% agar, increased c-di-GMP as a result of the pdcA mutation
resulted in increased biofilm formation.
pdcA affects toxin production and cytopathicity. Production of the C. difficile
toxins TcdA and TcdB is a stationary-phase phenomenon governed by multiple regu-
latory factors, including c-di-GMP and CodY (76). Production of TcdR, a sigma factor that
positively regulates tcdA and tcdB expression, is repressed by CodY when GTP and
BCAA are abundant in the cytoplasm (27). Expression of tcdR is positively regulated by
the sigma factor SigD (57, 58). Expression of sigD is repressed by elevated c-di-GMP,
making c-di-GMP a negative regulator of toxin gene expression (55, 57, 58). To
determine whether PdcA activity during stationary phase impacts toxin production,
TcdA protein produced by the 630 WT and pdcA::catPmutant strains, bearing the vector
or complementation plasmids indicated, was detected by Western blot analysis. The
pdcA::catP mutant strain with the vector (pRT1099) produced less TcdA than the WT
with the vector (Fig. 5A). Expression of pdcA under the control of its native promoter
(pRT1214) partially restored toxin production in the pdcA::catP mutant strain (Fig. 5A).
In contrast, expression of the pdcA E479A allele (pRT1662) encoding catalytically
inactive PdcA did not restore WT levels of toxin production (Fig. 5A). These results
support a role for PdcA in the regulation of TcdA production, specifically, the ability to
hydrolyze c-di-GMP.
To confirm that diminished TcdA production in the pdcA::catP mutant strain corre-
sponds to reduced cytopathicity against mammalian cells, we incubated MDCK-LA
epithelial cell monolayers overnight with filtered supernatants from stationary-phase
cultures of the WT and pdcA::catP mutant strains. C. difficile supernatants, as well as the
purified TcdA and TcdB toxins, disrupt the actin cytoskeleton and cause MDCK cell
rounding and death (77). We found that a 1:40 dilution of WT supernatant disrupted
cell-cell junctions and caused the epithelium to dissociate from the substrate (Fig. 5C).
A 1:40 dilution of pdcA::catP supernatant resulted in some individual cell detachment
but left the monolayer largely intact (Fig. 5C). A 1:80 dilution of WT supernatant caused
partial cell rounding and dissociation, leaving isolated patches of monolayer intact (Fig.
5C). A 1:80 dilution of pdcA::catP supernatant had almost no visible effect on monolayer
integrity (Fig. 5C). These observations are supported by quantitative evaluation of cell
viability after incubation with C. difficile supernatants. ATP levels, indicating cell viabil-
ity, were significantly lower in MDCK-LA cells treated with supernatant from the WT
strain than in cells treated with supernatant from the pdcA::catP mutant strain, indi-
cating reduced cytotoxicity of the pdcA::catP mutant (Fig. 5B).
To determine whether this reduced cytopathicity was due to reduced toxin produc-
tion, as opposed to another effect of the pdcA::catP mutation, we assessed the integrity
of the actin cytoskeleton, which is fluorescently labeled in MDCK-LA cells (78). Healthy
epithelial cells contain actin stress fibers at the basolateral surface and actin-based
microvillus protrusions at the apical surface (Fig. 5D, mock treated) (78). Incubation with
WT C. difficile lysate resulted in actin depolymerization and perturbed both of these
structures (Fig. 5D). Incubation with the same dilution of pdcA::catPmutant supernatant
left these subcellular actin structures largely intact (Fig. 5D). These data suggest that
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while the pdcA::catP mutation causes a moderate reduction in toxin synthesis, it is a
functionally significant difference and is sufficient to render the pdcA mutant strain less
cytopathic and cytotoxic to mammalian cells.
Growth phase regulation of pdcA expression limits the cellular behaviors
affected by PdcA. c-di-GMP inhibits swimming motility and toxin biosynthesis by
repressing the expression of flagellum and toxin genes in C. difficile (57, 58), and
c-di-GMP promotes biofilm formation (56, 60). However, the pdcA mutation only had a
detectable effect on biofilm formation and toxin production. These results were sur-
prising, because regulation of tcdA and tcdB by c-di-GMP occurs via SigD, which is
encoded in the flgB operon, whose expression is directly inhibited by c-di-GMP (57, 58).
We speculated that the directed effect of PdcA on a subset of c-di-GMP-regulated
processes could be due to restriction of pdcA expression to specific conditions and/or
to posttranslational control of PdcA function. Given that pdcA is a stationary-phase
gene (Fig. 2) and the observed biofilm and toxin phenotypes involve stationary-phase
bacteria, we hypothesized that temporal regulation of pdcA transcription limits PdcA
activity to stationary phase. If this is so, we predict that while pdcA expression during
the motility assay may not be high enough for the pdcAmutation to have a measurable
effect on bacterial swimming, the pdcA::catP mutation will still affect the expression of
FIG 5 pdcA influences C. difficile toxin production and cytopathicity. (A) TcdA production by 630/pRT1099
(vector control), pdcA::catP/pRT1099 (vector control), pdcA::catP/pRT1214 (complementation with pdcA WT
allele), and pdcA::catP/pRT1662 (complementation with pdcA E479A mutant allele). Strains were grown for
16 h in TY medium, and lysates were probed for TcdA by Western blot analysis. Samples were normalized
by adjustment to the OD of the culture. The data are expressed as a percentage of the 630/pRT1099 value
in each respective experiment. The mean values and standard errors from four independent assays are
shown. Data were analyzed by one-way analysis of variance and Tukey’s multiple-comparison test (**, P 
0.01; ****, P  0.0001 compared to 630/pRT1099; #, P  0.01 for the comparisons indicated). A represen-
tative Western blot analysis for TcdA is shown at the top. (B) Relative viability of MDCK-LA cells after
incubation with supernatants from 630 WT and pdcA::catP mutant strain stationary-phase cultures. Data
shown are mean values and standard deviations of three biological replicates and were analyzed by
two-way analysis of variance and Dunnett’s posttest (n.t., not treated; n.s. not significant; *, P  0.05; ***,
P  0.001). (C) Cytopathicity of 630 WT and pdcA::catP mutant strain supernatants against MDCK-LA cells
after 24 h of incubation. Scale bars, 10 m. (D) Effects of the 630 WT and pdcA::catP mutant strains on the
actin cytoskeleton (red). TIRF microscopy shows stress fibers at the basolateral cell surface. Epifluorescence
shows punctate microvilli at the apical surface. Scale bars, 10 m.
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both flagellum and toxin genes under stationary-phase conditions. To test this, we
compared the expression levels of toxin and flagellar genes in the 630 WT and
pdcA::catP mutant strains during exponential growth and during stationary phase. We
found that transcript levels of tcdA, the early flagellar gene flgB, and the flagellar
filament gene fliC were unaffected by the pdcA::catP mutation during exponential
phase (Fig. 6A). During stationary phase, when pdcA is expressed in WT cells, transcript
levels of tcdA and flgB were significantly lower in the pdcA::catP mutant strain than in
the parental strain (Fig. 6B). The 2-fold reduction observed in toxin gene expression was
consistent with the 2-fold reduction in TcdA protein production due to the pdcA::catP
mutation (Fig. 5A), supporting the conclusion that pdcA influences toxin production by
regulating gene expression. The fliC transcript was also somewhat reduced in the
pdcA::catP mutant strain during stationary phase, though the differences were not
statistically significant (P  0.059) (Fig. 6B). Expression of the WT pdcA gene in the
pdcA::catP mutant partially restored tcdA and fliC expression, though the differences
were not statistically significant (Fig. S3). The expression of the pdcA E479A mutant
allele had a more modest or no effect (Fig. S3). The challenges of complementing the
changes in gene expression in the pdcA::catP mutant are likely due to the small effects
of the pdcA mutation on transcript levels. Thus, the pdcA mutation affects the regula-
tion of flagellar genes in addition to the toxin genes under nutrient-limited conditions
in which pdcA is expressed, suggesting that genes expressed during stationary phase
have limited effects on motility through soft agar.
DISCUSSION
In this work, we expanded our prior understanding of c-di-GMP regulation in C.
difficile by characterizing the regulation and function of PdcA, 1 of 19 known or putative
c-di-GMP PDEs in C. difficile strain 630. We had previously reported that overexpression
of the PdcA-EAL domain had no discernible effect on C. difficile physiology or behavior
and speculated that cytoplasmic c-di-GMP levels were low enough under the condi-
tions studied to preclude a significant reduction upon ectopic PDE overproduction (55).
Here, we show that the activity of the PdcA regulatory domains and growth phase
regulation of pdcA expression determine PdcA-dependent phenotypes.
Disruption of pdcA significantly impacts biofilm formation and toxin biosynthesis.
Disruption of pdcA does not affect flagellar motility through soft agar, although the
FIG 6 Transcriptional regulation in the pdcA::catP mutant. (A) Relative transcript levels of tcdA, flgB, and
fliC in WT (black) and pdcA::catP mutant (gray) cells during exponential growth. (B) Relative transcript
levels during stationary phase. The mean values and standard deviations of five biological replicates are
shown. The data were analyzed by unpaired t test (**, P  0.05).
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pdcA mutation does affect flagellar gene expression during stationary phase. We
speculate that this distinction is due to the conditions of the motility assay. As flagellar
motility assays involve bacterial cells continuously expanding into conditions of low cell
density and fresh, nutrient-rich medium, the effects of stationary-phase genes may not
be readily apparent. In contrast, C. difficile toxins are produced in stationary-phase
cultures in vitro (27) and biofilms are likely to contain stationary-phase bacteria, making
it possible to detect the effects of a pdcA mutation. Thus, CodY inhibition of pdcA
transcription during exponential growth results in temporal regulation that directs
PdcA activity toward the c-di-GMP-regulated processes that occur during stationary
phase.
In vitro assays of PDE activity of PdcA and mutant derivatives indicate that the PAS
domain is required for full activity and suggest that GTP binding to the GGDEF domain
stimulates the enzymatic activity of the EAL domain. These results are supported by in
vivo analyses. While ectopic expression of WT, full-length pdcA significantly increased
swimming motility, expression of the mutant derivatives did not, although they were
catalytically active. Together, these data indicate that PdcA activity is regulated at the
protein level. The ability of degenerate GGDEF domains to regulate a tandem EAL
domain in response to GTP has been demonstrated (68, 79), and it remains possible
that the PdcA PAS domain provides another as-yet-uncharacterized means of post-
translational regulation. Of the 19 C. difficile EAL family c-di-GMP PDEs, 18 contain
degenerate GGDEF domains (80), suggesting that c-di-GMP turnover in C. difficile may
be generally linked to GTP availability (65–67). As c-di-GMP synthesis utilizes GTP as a
substrate, linking c-di-GMP hydrolysis to GTP availability may limit c-di-GMP turnover
under nutrient-limiting growth conditions when intracellular GTP availability is limited
(33, 34, 65, 81–83).
A DNA region encompassing the 5= end of the pdcA ORF and putative promoter was
identified as a target of CodY binding (27). That study did not identify a consensus CodY
binding site in the pdcA promoter region. However, we demonstrate that CodY binds
directly to the pdcA promoter region in vitro. We note that Dineen et al. allowed up to
three mismatches from the CodY consensus, whereas the putative CodY binding site
upstream of the pdcA coding sequence contains four bases that deviate from the
consensus (Fig. S2). Lower concentrations of CodY bound to and shifted the DNA
fragment containing the ilvC promoter, suggesting higher affinity of CodY for the ilvC
promoter than for the pdcA promoter, consistent with the greater transcriptional
repression by CodY observed for ilvC.
Regulation of pdcA transcription by CodY further links PdcA activity to cytoplasmic
GTP. Interestingly, CodY and PdcA appear to have dramatically different affinities for
GTP in vitro. Purified C. difficile CodY is activated in vitro only by very large (10,000-fold)
molar excesses of GTP (30, 84), while purified PdcA is activated by an equimolar amount
of GTP, suggesting that PdcA activity may be stimulated by GTP concentrations too low
to activate CodY. This suggests that fluctuations in cytoplasmic GTP levels can impact
the transcription of the pdcA gene, as well as modulate the activity of previously
expressed PdcA protein (Fig. 7). At limiting GTP concentrations, the enzymatic activity
of PdcA is likely to be low, but deactivation of CodY would allow pdcA transcription to
increase the overall level of PdcA in the cell cytoplasm. At the other extreme, very high
GTP levels would inhibit pdcA transcription via CodY, but the activity of existing PdcA
molecules would be maximal. In both B. subtilis and S. aureus, CodY functions as a
“dimmer” rather than a binary on-off switch, repressing certain genes differentially in
response to moderate or severe levels of nutrient limitation (85, 86). It is likely that in
C. difficilemany circumstances in vivo could feature intermediate cytoplasmic GTP levels
low enough to allow some pdcA expression but high enough to permit stimulation of
PdcA enzymatic activity (Fig. 7). As intracellular GTP concentrations in bacteria are
highly dynamic and responsive to the addition of nutrients to the growth medium, with
transient 70 to 80% decreases in the cytoplasmic GTP concentration and concomitant
rises in ppGpp occurring upon stationary phase onset or during starvation (32–34,
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81–84, 87), the net PdcA activity in the cell may be highly responsive to intracellular
GTP availability and extracellular nutrient availability.
c-di-GMP signaling is affected by nutrient limitation in other bacterial species. For
example, multiple Pseudomonas species have been shown to increase the expression of
PDE genes in response to nutrient starvation, although these genes have been impli-
cated in biofilm dispersal rather than biofilm formation or motility (88, 89). Similarly, a
bifunctional DGC-PDE protein affects the long-term survival of Mycobacterium smeg-
matis under nutrient-limiting conditions (90). Nutrient limitation is a clinically relevant
stress for intestinal pathogens: the healthy mammalian large intestine is not rich in
usable nutrient sources for C. difficile, as mono- and disaccharides and amino acids are
largely absorbed by the host in the small intestine (91, 92). The recent discovery that
a “nutrient bloom” in response to antibiotic disruption of the gut microbiome increases
susceptibility to C. difficile infection suggests that nutrient availability is a major barrier
to C. difficile survival in a healthy host (93). It is worth noting that pdcA (CD630_15150)
expression is also increased by heat shock, another clinically relevant stress (94), raising
the possibility that this PDE controls a more general stress response in C. difficile.
This is the first report linking any c-di-GMP-regulated phenotypes in C. difficile to the
activity of a specific c-di-GMP metabolism protein, underscoring the importance of
analyzing individual PDE and DGC enzymes. Future studies to more precisely identify
the extracellular nutrient signals that affect PdcA activity will help define the environ-
mental conditions that influence c-di-GMP signaling in C. difficile. Further work to
determine the chemical signals that modulate intracellular c-di-GMP in C. difficile is vital,
given the role of this second messenger in the control of processes central to patho-
genesis.
MATERIALS AND METHODS
Bacterial strains and growth conditions. The bacterial strains and plasmids used in this study are
listed in Table S1. C. difficile 630 and derivative strains were routinely grown in BHIS, supplemented as
specified, in an anaerobic chamber with an atmosphere of 85% N2, 5% CO2, and 10% H2. Medium for
growth of strains containing pMC123 derivative plasmids was supplemented with 10 g/ml thiampheni-
col (BHIS-Tm). Medium for growth of strains containing the integrated pSD21 codY insertional mutation
was supplemented with 2 g/ml erythromycin (BHIS-Erm). Medium for growth of strains containing
pRT1099, pRT1214, or pRT1662 was supplemented with 500 g/ml spectinomycin unless indicated
otherwise. Escherichia coli strains were propagated in Luria-Bertani (LB) medium or on LB agar plates
containing 50 g/ml ampicillin, 10 g/ml chloramphenicol, and/or 50 g/ml spectinomycin, as needed,
at 37°C under aerobic conditions.
Plasmid and strain construction. All restriction enzymes and DNA polymerase (Phusion) were
purchased from New England BioLabs. The sequences of the oligonucleotides used in this study are listed
in Table S2.
The creation of pMMBneo::pdcA and pMMBneo::pdcA-EAL has previously been described (55).
Purified pMMBneo::pdcA (55) was used as the PCR template to generate E. coli expression constructs. A
mutant allele of pdcA (CD630_1515) in which the GGDEF motif, sequence DGDEM, is mutated to alanines
was generated by splicing by overhang extension (SOE) PCR. Primers pdcAF and pdcAgaR were used to
amplify the upstream fragment, and primers pdcAgaF and pdcAR were used to amplify the downstream
fragment, and they were subsequently spliced together. A PdcA truncation lacking the N-terminal PAS
FIG 7 GTP levels inversely regulate the production and activity of PdcA enzymes. At very low cytoplasmic
GTP levels, the activity level of existing PdcA proteins will be low, but CodY will be deactivated to permit
additional pdcA transcription. At intermediate concentrations, both pdcA transcription and PdcA activity
will be responsive to GTP fluctuations. At high GTP levels, pdcA transcription will be inhibited but existing
PdcA will be very active.
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domain (residues 1 to 251) was amplified from pMMBneo::pdcA with primers pdcAdpF and pdcAR. The
resulting fragments were digested with KpnI and PstI and ligated to similarly digested pMMBneo (95).
Kanamycin-resistant transformants of E. coli DH5 were screened for the desired plasmids by PCR with
gene-specific primers and plasmid-specific primers 67EHF and 67EHR. The plasmids were introduced by
electroporation into E. coli BL21 for gene expression and protein purification.
For gene expression in C. difficile, pPdcA (55) was the PCR template for generating a GGDEF point
mutant and a ΔPAS truncation with the primers listed above. The resulting fragments were digested with
KpnI and PstI and ligated to similarly digested pMC-Pcpr. Chloramphenicol-resistant transformants of E.
coli DH5 were screened for the desired plasmids by PCR with primers pUCmscF and m13R. These
plasmids were transformed by electroporation into strain HB101(pRK24) to allow conjugation with C.
difficile. The HB101(pRK24) plasmid donor strains were mated with C. difficile strain 630 as previously
described (55). Transconjugants were selected on BHIS-Tm supplemented with 100 g/ml kanamycin
and screened by PCR with pUCmscF and m13R to confirm the presence of a plasmid with an insert of
the correct size and with primers tcdBF and tcdBR to confirm the isolation of C. difficile. At least two
isolates were obtained for each conjugation. The generation of pPdcA and pPdcA-EAL and their
introduction into C. difficile were previously described (55).
The pdcA::catP mutant was created by double homologous recombination essentially as previously
described, with some modifications (75). Allelic-exchange vector pMC234 was created by the stepwise
addition of two DNA fragments to pUC19 (96). A 390-bp oriT fragment was PCR amplified from pJIR1456
(97) with primers oMC15 and oMC16, digested with EcoO1091/AatII, and ligated into pUC19 to give
plasmid pMC95 (98). A 1,043-bp fragment containing the C. perfringens catP gene was then amplified
from pJIR1456 (97) with primers oMC2 and oMC143, digested with BamHI, and ligated into pMC95 to
yield plasmid pMC234. The 2,000-bp regions upstream and downstream of the pdcA ORF were amplified
with primers pdcAf1 and pdcAr1 or pdcAf2 and pdcAr2, respectively. The 5= flanking region was digested
with EcoRI and KpnI, and the 3= flanking region was digested with SalI and PstI. Fragments were
sequentially ligated into pMC234, flanking the catP gene, to create pMC234::pdcA::catP, which was
transformed by electroporation into HB101(pRK24) for conjugation with C. difficile 630. Isolates with a
single-crossover integration of pMC234::pdcA::catP were selected on BHIS-Tm plates supplemented with
100 g/ml kanamycin to select against HB101(pRK24). Thiamphenicol-resistant single-crossover isolates
were confirmed by PCR with primers within the sequences flanking the pdcA ORF, which yield a 2.1-kb
product when amplifying pdcA from the chromosome and a 1.1-kb product when amplifying catP from
the integrated plasmid. Primers PdcAF and PdcAR, which amplify the pdcA ORF but not the flanking
sequences, were used to specifically detect pdcA, and oMC143 and oMC2 were used to specifically detect
catP. Additional screening was performed with the flanking primer pair pdcAbamHI and pdcApstI or
pdcAbamHI and PdcAR0, which will amplify the WT pdcA ORF on the chromosome but yield no product
from the integrated vector. Isolates were passaged once in BHIS-Tm broth and subsequently in BHIS with
no antibiotic. Each passage was plated on BHIS agar, and individual colonies were screened by PCR with
multiple pairs of primers. After eight passages, we obtained a strain in which the pdcA gene (2,094 bp)
was replaced with the catP gene (1,043 bp). The loss of integrated pMC234::pdcA::catP was confirming by
PCR screening for the bla gene on the vector with primers blaF and blaR.
To create vectors encoding spectinomycin resistance, the Enterococcus faecalis aad9 gene was
amplified from pBTS (gift from A. R. Richardson) (99) with primers aad9F_EcoRV and aad9R_EcoRV and
digested with EcoRV. pMC123 was digested with SapI and PciI to remove the catP cassette and then
treated with Klenow fragment to blunt the ends. The aad9 gene was ligated into pMC123 lacking catP,
generating pRT1099. pdcA and the 521 bp upstream of the translational start site were amplified from
C. difficile genomic DNA with primers pdcApromF and pdcApromR and ligated into pRT1099 at the SphI
and BamHI restriction sites to create pRT1214. A pdcA E479A mutant allele with an alanine substitution
of glutamic acid in the EAL motif was generated by SOE PCR with primers pdcAeaF and pdcAeaR. Primers
pdcApromF and pdcAeaR were used to amplify the upstream fragment of C. difficile 630 genomic DNA,
and primers pdcAeaF and pdcApromR were used to amplify the downstream fragment. The fragments
were spliced together and cloned into pRT1099 at the SphI and BamHI restriction sites, yielding pRT1662.
The plasmids were confirmed by PCR and sequencing of the cloned fragment and then introduced into
C. difficile by conjugation via HB101(pRK24).
RNA isolation and qRT-PCR. RNA was isolated as described previously from C. difficile cultures
grown in BHIS with the appropriate antibiotics to exponential or early stationary phase as previously
indicated (55). Exponential-phase samples were collected at an optical density at 600 nm (OD600) of 0.4
to 0.6, and stationary-phase samples were collected 1 to 2 h after logarithmic growth ended. After DNase
treatment (Ambion), cDNA samples were prepared from 500 ng of RNA with random hexamers and the
Tetro cDNA synthesis kit (Bioline). Real-time PCR was done with 4 ng of template cDNA with the SensiMix
SYBR and fluorescein kit (Bioline). Primers (Table S2) were designed with the PrimerQuest tool from IDT
DNA Technologies, and forward and reverse primers were named in accordance with the pattern
gene-qF and gene-qR, respectively. At least three independent samples were analyzed. The rpoC
transcript was used as the reference gene (55). Controls with no reverse transcriptase were included for
all templates and all primer sets. The data were analyzed by the 2ΔΔCT method, with normalization to
rpoC and the stated reference condition or strain (55).
Protein purification. BL21 expression strains were grown at 37°C to an OD600 of 0.1 to 0.15, at which
point the cultures were shifted to 25°C and expression was induced with 1 mM isopropyl--D-
thiogalactopyranoside (IPTG) for 16 h. Cells were collected by centrifugation and lysed by sonication in
His6 buffer (10 mM Tris-HCl [pH 7.8], 300 mM NaCl, 50 mM NaH2PO4, 10% glycerol) supplemented with
1 mM phenylmethylsulfonyl fluoride (PMSF) and 1 mg/ml lysozyme (55). Lysates were clarified by
Purcell et al. Infection and Immunity
September 2017 Volume 85 Issue 9 e00347-17 iai.asm.org 12
centrifugation at 12,000  g for 30 min at 4°C, and the soluble fractions were incubated with HisPur
Ni-nitrilotriacetic acid (NTA) resin (Thermo Scientific) for 2 h at 4°C. Samples were centrifuged at 700 
g for 2 min at 4°C, and then the resin was suspended in His6 buffer, rocked for 15 min at 4°C, and
centrifuged at 700  g for 2 min at 4°C. This washing protocol was repeated twice with His6 buffer
containing 100 mM imidazole. Proteins were eluted in His6 buffer with 250 mM imidazole. Purified
proteins were confirmed by SDS-PAGE and staining with Coomassie brilliant blue (55). Protein concen-
trations were measured by UV spectroscopy by using 280 values calculated from ExPASY ProtParam
(100). Purified proteins were stored at 4°C and used for enzymatic assays within 5 days of purification.
Histidine-tagged CodY was purified from E. coli BL21 bearing pEAV1 (30). The strain was grown at
37°C to an OD600 of 0.4 to 0.5, and then IPTG was added to a final concentration of 1 mM. After an
additional 5 h of growth at 37°C, cells were collected by centrifugation. The pellet was suspended in
BugBuster Lysis Solution (EMD Millipore), and cells were lysed in accordance with the manufacturer’s
protocol. The soluble fraction was collected by centrifugation and incubated with HisPur Ni-NTA resin for
2 h at 4°C. The resin was washed with CodY buffer (20 mM Tris [pH 8], 125 mM KCl, 50 mM NaH2PO4, 10%
glycerol, 1 mM PMSF) containing 50 mM imidazole. CodY was eluted with CodY buffer containing 200
mM imidazole. Amicon Ultrafree columns with a 3,000-Da molecular mass cutoff (EMD Millipore) were
used for buffer exchange and protein concentration into CodY buffer. Protein concentration was
determined with the Pierce BCE Protein Assay kit (Thermo Scientific). Glycerol was added to a final
concentration of 20%, and the protein was stored at 20°C.
In vitro enzymatic assays. Purified PdcA, PdcA(GA), PdcA-ΔPAS, and PdcA-EAL were assayed for PDE
activity as previously described (55). The radiolabeled c-di-GMP substrate was synthesized by using the
characterized C. difficile DGC DccA and purified as described previously (101, 102). The reaction was
initiated by the addition of radiolabeled substrate, and 1-l aliquots were taken for analysis at 6, 30, 60,
and 120 s. Reaction mixtures lacking enzyme were used as negative controls. Where specified, 0, 1, 20,
or 100 M GTP was added to the reaction mixtures. Aliquots were analyzed by thin-layer chromatog-
raphy as described previously (102). All reaction mixtures were prepared in triplicate. Enzymatic activity
was recorded as the percentage of 32P-labeled c-di-GMP cleaved over time.
EMSAs. Binding of CodY to the pdcA promoter, as well as an ilvC promoter positive control, was
assessed by EMSA essentially as described previously (30). A region encompassing the first 145 nucle-
otides of the pdcA coding sequence and 261 upstream bases was amplified from C. difficile 630
chromosomal DNA by PCR with pdcAemsaF and pdcAemsaR. The 423-bp ilvC promoter region was
amplified with OSD107 and OSD108 (27). As a negative control, a 133-bp fragment of the gbpA gene was
amplified from V. cholerae C6706 chromosomal DNA with primers gbpAqF and gbpAqR (103). Binding
reactions between CodY and putative target DNA took place in a mixture of 20 mM Tris (pH 8); 50 mM
sodium glutamate; 10 mM MgCl2; 5 mM EDTA; 0.1% Tween 20; 5% glycerol; 2 mM GTP; and 100 mM each
leucine, isoleucine, and valine (30). Binding reaction mixtures contained serially diluted CodY, 50 ng of
V. cholerae gbpA DNA, and 70 ng of either ilvC promoter DNA or pdcA promoter DNA and were incubated
at room temperature for 30 min. Samples were separated by electrophoresis in 10% Mini-PROTEAN TGX
precast gels (Bio-Rad) in a running buffer consisting of 25 mM Tris base, 192 mM glycine, and 10 mM
isoleucine-leucine-valine. Gels were stained for 1 h with GelRed (Biotium) and imaged under UV light.
c-di-GMP quantification by UPLC-MS. Nucleotides were extracted from C. difficile and quantified as
previously described (60). Briefly, individual colonies of the 630 WT and pdcA::catP mutant strains were
grown anaerobically at 37°C for 7 h. These starter cultures were diluted 1:100 in 50 ml of BHIS medium
and grown anaerobically at 37°C for 10 h to an OD600 of 1.6 to 1.8. Nucleotides were isolated from the
supernatant through methanol-acetonitrile extraction as previously described (60). The total protein
content of the insoluble fraction of each sample was quantified by the colorimetric BCA assay kit (Thermo
Scientific). Nucleotide samples were dried overnight with a vacuum concentrator at room temperature
and suspended in 100 l of distilled H2O/200 l of extracted nucleotide. Samples were stored at 80°C
until use. Aliquots (10 l) were injected into a TSQ Quantum Ultra triple-quadrupole mass analyzer
(Thermo Scientific, Waltham, MA). The analytes were separated on a Waters HSS T3 UPLC column (2.1 by
100 mm, 1.8 m) by gradient elution from 99.9% solvent A (10 mM ammonium formate in water) to 40%
solvent B (10 mM ammonium formate in methanol) for 2 min, followed by column flushing at 90%
solvent B for 2.5 min and column re-equilibration for 3.5 min. The column effluent was diverted to waste
for the first 2 min. The mass spectrometer parameters were as follows: positive-ion electrospray mode;
spray voltage, 3.5 kV; vaporizer temperature, 250°C; sheath gas, 35 arbitrary units; auxiliary gas, 30
arbitrary units; capillary temperature, 285°C; collision gas pressure, 1.5 mtorr (0.19 Pa). c-di-GMP was
detected by monitoring precursor ion-to-fragment ion transitions (m/z 691 to152 [collision energy, 35]
and m/z 691 to 540 [collision energy, 21]) and quantified by using a calibration curve of known
concentrations of pure c-di-GMP (Biolog Life Science Institute, Bremen, Germany) ranging from 0.1 to
1,000 nM. Cytoplasmic c-di-GMP concentrations were normalized to the total protein content of the
samples. Four independent samples were analyzed for each strain.
Motility assays. Motility experiments were performed as previously described (55). Briefly, individual
colonies were inoculated with sterile toothpicks into 0.3% agar plates containing BHIS or BHIS-Tm with
0 or 5 g/ml nisin. The plates were incubated at 37°C in an anaerobic chamber for 72 h. The diameters
of motility growth were measured every 24 h for three independent experiments.
Detection of TcdA by Western blot analysis. Overnight cultures were diluted 1:100 in tryptone-
yeast (TY) medium with 250 g/ml spectinomycin (104). After 16 h of growth under anaerobic conditions
at 37°C, bacteria were collected from 3 ml of culture by centrifugation and suspended in SDS-PAGE
loading buffer. Samples were normalized to the ODs of the cultures for loading onto 4 to 15% TGX
polyacrylamide gradient gels (Bio-Rad). After electrophoresis, the samples were transferred to nitrocel-
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lulose membranes. Blots were probed with a mouse anti-TcdA antibody (Novus Biologicals) and an
IR800-conjugated goat anti-mouse secondary antibody (Thermo Fisher) and visualized on an Odyssey
Imager (Li-COR Biotechnology). The anti-TcdA signal was quantified with Image Studio (Li-COR Biotech-
nology). Four independent experiments were done, and the data are expressed as percentages of the
strain 630/pRT1099 (WT with vector) value in that experiment.
Biofilm assays. Untreated polystyrene 24-well culture plates (Corning) were kept in an anaerobic
chamber for a minimum of 72 h prior to use. Overnight cultures were diluted 1:50 in 1 ml of BHIS
supplemented with 1% glucose and 50 mM sodium phosphate buffer (pH 7.5). For experiments with C.
difficile bearing pRT1099 and derivatives, 250 g/ml spectinomycin was added to the medium. After
incubation at 37°C for 24 h under anaerobic conditions, the culture supernatant was removed and the
adherent biomass was washed once with phosphate-buffered saline (PBS) and stained for 30 min with
0.1% (wt/vol) crystal violet in water. Excess crystal violet was removed, and the wells were washed twice
with PBS. The bound crystal violet was solubilized with 95% ethanol. The absorbance at 570 nm was
measured with a Synergy HT microplate reader (BioTek). Experiments were done at least three times.
Analysis of cytopathic effects on target cells. The WT and pdcA::catPmutant C. difficile strains were
grown in BHIS medium supplemented with 50 mM sodium phosphate buffer (pH 7.5) for 24 h. Cultures
were centrifuged for 5 min at 2,000  g, and supernatants were filtered through 0.45-m sterile nylon
filters (Fisher). MDCK cells stably expressing LifeAct-tagRFP-T (ibidi USA) (78) were generated as de-
scribed in reference 105. Briefly, type II MDCK cells (clone T23; Invitrogen) were cotransfected with
pLL5/LifeAct-tagRFP-T and pTK-Hyg. The transfected cells were cultured with selection medium contain-
ing 250 g/ml hygromycin B (Roche). Clones were selected by red fluorescent protein (RFP) fluorescence
and confirmed by Western blot analysis for tagRFP protein and are termed MDCK-LA cells here. For
cytopathicity assays, MDCK-LA cells were seeded at high density and grown for 2 days after confluence
was reached in Dulbecco’s modified Eagle medium supplemented with 10% fetal bovine serum (F2442;
Sigma) in 24-well tissue culture plates (3524; Costar) at 37°C and 5% CO2. Samples were then incubated
with the dilutions of bacterial supernatant indicated at 37°C and 5% CO2 for 24 h. For quantitative
measurements of cell viability, ATP content was measured with the CellTiter-Glo Luminescent Cell
Viability assay (Promega).
MDCK cells were imaged with a Nikon TiE microscope equipped with a Hamamatsu Orca-Flash 4.0
camera. Cells in plates were imaged with Nikon 10/numerical aperture (NA) 0.25 (Plan, Ph1 DL) and
20/NA 0.75 (Plan Apo, Ph2 DM) objectives in conjunction with phase-contrast and differential inter-
ference contrast optical components, as indicated. For visualization of the actin cytoskeleton, cells were
grown in 35-mm glass bottom dishes (P35G-1.5-20-C; MatTek) and visualized with the same microscope
with a laser with a 568-nm wavelength for total internal reflection fluorescence (TIRF) and epifluores-
cence through a 60/NA 1.45 (Plan Apo TIRF) objective. All imaging data were collected with Nikon
Elements. Image analysis was performed with Nikon Elements and ImageJ.
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